- Home
- CLYM vs CKPT Comparison
CLYM vs CKPT Comparison
Compare CLYM & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- CKPT
- Stock Information
- Founded
- CLYM 2018
- CKPT 2014
- Country
- CLYM United States
- CKPT United States
- Employees
- CLYM N/A
- CKPT N/A
- Industry
- CLYM
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- CKPT Health Care
- Exchange
- CLYM NYSE
- CKPT Nasdaq
- Market Cap
- CLYM 201.7M
- CKPT 214.4M
- IPO Year
- CLYM 2021
- CKPT 2017
- Fundamental
- Price
- CLYM $1.95
- CKPT $3.61
- Analyst Decision
- CLYM
- CKPT Strong Buy
- Analyst Count
- CLYM 0
- CKPT 3
- Target Price
- CLYM N/A
- CKPT $10.33
- AVG Volume (30 Days)
- CLYM 264.1K
- CKPT 2.4M
- Earning Date
- CLYM 11-12-2024
- CKPT 11-12-2024
- Dividend Yield
- CLYM N/A
- CKPT N/A
- EPS Growth
- CLYM N/A
- CKPT N/A
- EPS
- CLYM N/A
- CKPT N/A
- Revenue
- CLYM N/A
- CKPT $47,000.00
- Revenue This Year
- CLYM N/A
- CKPT N/A
- Revenue Next Year
- CLYM N/A
- CKPT $216,182.69
- P/E Ratio
- CLYM N/A
- CKPT N/A
- Revenue Growth
- CLYM N/A
- CKPT N/A
- 52 Week Low
- CLYM $1.86
- CKPT $1.38
- 52 Week High
- CLYM $11.55
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- CKPT 41.64
- Support Level
- CLYM N/A
- CKPT $2.98
- Resistance Level
- CLYM N/A
- CKPT $4.44
- Average True Range (ATR)
- CLYM 0.00
- CKPT 0.42
- MACD
- CLYM 0.00
- CKPT -0.10
- Stochastic Oscillator
- CLYM 0.00
- CKPT 25.66
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.